OTCMKTS:MTST

MetaStat Competitors

$0.02
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.02
$0.05
52-Week Range
$0.00
Now: $0.02
$0.05
VolumeN/A
Average Volume21,100 shs
Market Capitalization$117,576.00
P/E RatioN/A
Dividend YieldN/A
Beta-4.21

Competitors

MetaStat (OTCMKTS:MTST) Vs. TRPXD, BSPM, HSTC, EPRSQ, PFSCF, and PZRXQ

Should you be buying MTST stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to MetaStat, including Therapix Biosciences (TRPXD), Biostar Pharmaceuticals (BSPM), HST Global (HSTC), EPIRUS Biopharmaceuticals (EPRSQ), ProMetic Life Sciences (PFSCF), and PhaseRx (PZRXQ).

MetaStat (OTCMKTS:MTST) and Therapix Biosciences (OTCMKTS:TRPXD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

14.3% of Therapix Biosciences shares are held by institutional investors. 8.5% of MetaStat shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for MetaStat and Therapix Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MetaStat0000N/A
Therapix Biosciences0000N/A

Valuation and Earnings

This table compares MetaStat and Therapix Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetaStat$20,000.005.88$-3,180,000.00N/AN/A
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A

MetaStat has higher revenue and earnings than Therapix Biosciences.

Profitability

This table compares MetaStat and Therapix Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetaStatN/AN/AN/A
Therapix BiosciencesN/AN/AN/A

Summary

MetaStat beats Therapix Biosciences on 3 of the 4 factors compared between the two stocks.

Biostar Pharmaceuticals (OTCMKTS:BSPM) and MetaStat (OTCMKTS:MTST) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Biostar Pharmaceuticals and MetaStat, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biostar Pharmaceuticals0000N/A
MetaStat0000N/A

Earnings and Valuation

This table compares Biostar Pharmaceuticals and MetaStat's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biostar PharmaceuticalsN/AN/AN/AN/AN/A
MetaStat$20,000.005.88$-3,180,000.00N/AN/A

Biostar Pharmaceuticals has higher earnings, but lower revenue than MetaStat.

Profitability

This table compares Biostar Pharmaceuticals and MetaStat's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biostar PharmaceuticalsN/AN/AN/A
MetaStatN/AN/AN/A

Risk & Volatility

Biostar Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, MetaStat has a beta of -4.21, indicating that its stock price is 521% less volatile than the S&P 500.

HST Global (OTCMKTS:HSTC) and MetaStat (OTCMKTS:MTST) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for HST Global and MetaStat, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HST Global0000N/A
MetaStat0000N/A

Profitability

This table compares HST Global and MetaStat's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HST GlobalN/A-1,715.09%-13,300.29%
MetaStatN/AN/AN/A

Earnings and Valuation

This table compares HST Global and MetaStat's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HST GlobalN/AN/A$430,000.00N/AN/A
MetaStat$20,000.005.88$-3,180,000.00N/AN/A

HST Global has higher earnings, but lower revenue than MetaStat.

Volatility & Risk

HST Global has a beta of -0.52, meaning that its stock price is 152% less volatile than the S&P 500. Comparatively, MetaStat has a beta of -4.21, meaning that its stock price is 521% less volatile than the S&P 500.

Summary

MetaStat beats HST Global on 3 of the 5 factors compared between the two stocks.

MetaStat (OTCMKTS:MTST) and EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares MetaStat and EPIRUS Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetaStat$20,000.005.88$-3,180,000.00N/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A

EPIRUS Biopharmaceuticals has lower revenue, but higher earnings than MetaStat.

Analyst Recommendations

This is a breakdown of current ratings and price targets for MetaStat and EPIRUS Biopharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MetaStat0000N/A
EPIRUS Biopharmaceuticals0000N/A

Profitability

This table compares MetaStat and EPIRUS Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetaStatN/AN/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/A

Risk and Volatility

MetaStat has a beta of -4.21, suggesting that its share price is 521% less volatile than the S&P 500. Comparatively, EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its share price is 503% more volatile than the S&P 500.

ProMetic Life Sciences (OTCMKTS:PFSCF) and MetaStat (OTCMKTS:MTST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Profitability

This table compares ProMetic Life Sciences and MetaStat's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
MetaStatN/AN/AN/A

Insider & Institutional Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. 8.5% of MetaStat shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

ProMetic Life Sciences has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, MetaStat has a beta of -4.21, indicating that its share price is 521% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProMetic Life Sciences and MetaStat, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
MetaStat0000N/A

Valuation & Earnings

This table compares ProMetic Life Sciences and MetaStat's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
MetaStat$20,000.005.88$-3,180,000.00N/AN/A

MetaStat has lower revenue, but higher earnings than ProMetic Life Sciences.

Summary

MetaStat beats ProMetic Life Sciences on 6 of the 9 factors compared between the two stocks.

MetaStat (OTCMKTS:MTST) and PhaseRx (OTCMKTS:PZRXQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

MetaStat has a beta of -4.21, suggesting that its share price is 521% less volatile than the S&P 500. Comparatively, PhaseRx has a beta of -0.86, suggesting that its share price is 186% less volatile than the S&P 500.

Valuation and Earnings

This table compares MetaStat and PhaseRx's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetaStat$20,000.005.88$-3,180,000.00N/AN/A
PhaseRxN/AN/AN/AN/AN/A

PhaseRx has lower revenue, but higher earnings than MetaStat.

Analyst Ratings

This is a summary of current ratings and price targets for MetaStat and PhaseRx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MetaStat0000N/A
PhaseRx0000N/A

Profitability

This table compares MetaStat and PhaseRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetaStatN/AN/AN/A
PhaseRxN/AN/AN/A


MetaStat Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRPXD
Therapix Biosciences
0.0$9.15flat$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17flat$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02flat$374,000.00N/A0.00Increase in Short Interest
Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03flat$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09flat$124,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$35.08flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
HRBR
Harbor Diversified
0.0$1.16flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00Gap Up
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Decrease in Short Interest
News Coverage
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.07flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.03flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.07flat$0.00$26.09 million0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00Gap Down
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.07flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.02flat$0.00N/A0.00
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.